[Skip to Content]
[Skip to Content Landing]
Observation
October 2018

Birdshot-like Chorioretinopathy Associated With Pembrolizumab Treatment

Author Affiliations
  • 1Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania
  • 2Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania
JAMA Ophthalmol. 2018;136(10):1205-1207. doi:10.1001/jamaophthalmol.2018.1851

Pembrolizumab, an immunotherapeutic agent against the programmed cell death 1 (PD-1) receptor on T cells, is approved to treat metastatic cancers, particularly cutaneous melanoma. Activated PD-1 reduces T-cell responses against tumors; pembrolizumab blocks this receptor, enhancing T-cell response to tumors.1 Ocular adverse events associated with pembrolizumab treatment include uveitis and conjunctivitis.1 Uveitis has been documented in 1% of treated patients; most such cases have been classified as anterior uveitis.1 Herein, we describe bilateral birdshot-like chorioretinopathy after pembrolizumab immunotherapy in a patient with cutaneous melanoma metastases.

×